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Abstract
Acute rejection, a common complication of lung transplantation, may promote obliterative bronchiolitis leading to graft
failure in lung transplant recipients. During acute rejection episodes, CD8+ T cells can contribute to lung epithelial
injury but the mechanisms promoting and controlling CD8-mediated injury in the lung are not well understood. To
study  the  mechanisms  regulating  CD8+  T  cell–mediated  lung  rejection,  we  used  a  transgenic  model  in  which
adoptively transferred ovalbumin (OVA)-specific cytotoxic T lymphocytes (CTL) induce lung injury in mice expressing
an ovalbumin transgene in the small airway epithelium of the lungs (CC10-OVA mice). The lung pathology is similar
to findings in humans with acute lung transplant. In the presence of an intact immune response the inflammation
resolves by day 30. Using CC10-OVA.RAG-/- mice, we found that CD4+ T cells and ICOS+/+ T cells were required for
protection against lethal lung injury, while neutrophil depletion was not protective. In addition, CD4+Foxp3 + ICOS+ T
cells were enriched in the lungs of animals surviving lung injury and ICOS+/+ Tregs promoted survival in animals that
received ICOS-/- T cells. Direct comparison of ICOS-/- Tregs to ICOS+/+ Tregs found defects in vitro but no differences
in  the  ability  of  ICOS-/-  Tregs  to  protect  from  lethal  lung  injury.  These  data  suggest  that  ICOS  affects  Treg
development but is not necessarily required for Treg effector function.
Citation: Wu Q, Gardiner GJ, Berry E, Wagner SR, Lu T, et al. (2013) ICOS-Expressing Lymphocytes Promote Resolution of CD8-Mediated Lung Injury in
a Mouse Model of Lung Rejection. PLoS ONE 8(8): e72955. doi:10.1371/journal.pone.0072955
Editor: Lucienne Chatenoud, Université Paris Descartes, France
Received May 30, 2012; Accepted July 21, 2013; Published August 13, 2013
Copyright: © 2013 Wu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by NIH/NIAID K08AI059105 (RAS), American Society of Transplantation/Wyeth (RAS), NIH/NIAID R01AI67697 (AIS),
Blowitz-Ridgeway Foundation (AIS), American Cancer Society–Illinois Division (J.L.C.), Irvington Institute Fellowship Program of the Cancer Research
Institute (J.L.C.), Scientist Development Grant, American Heart Association (J.L.C), Roche Organ Transplantation Research Foundation (BDM and ADL)
and NIH R01CA069212 (ADL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: shilling@uic.edu
Introduction
CD8+ T cells are important mediators of the adaptive immune
response  to  pathogens  and  tumors  but  their  function  as
cytotoxic  T  lymphocytes  (CTL)  can  also  lead  to
immunopathology. During viral infections bystander activation
and  recruitment  of  inflammatory  cells  can  lead  to  prolonged
lung  injury  and  collateral  damage  to  the  tissue  [1].  For  lung
transplants, CD8+ T cells may play a critical role in driving the
alloimmune  response  that  leads  to  acute  rejection  and  may
promote  chronic  rejection  [2–6].  Increased  pro-inflammatory
cytokine  producing  CD8+  T  cells  can  be  found  in  the
bronchoalveolar  lavage  (BAL)  during  episodes  of  acute  lung
transplant rejection in humans [7]. CD8+ T cells have also been
found  to  be  capable  of  inducing  rejection  in  the  lung
independent of CD4+ T cells in a mouse model of orthotopic
lung  transplant  [7,8].  However,  the  mechanisms  to  control
CD8+ mediated injury and damage to lung tissue are not well
understood.
Several types of T cell subpopulations have been shown to
display  immunoregulatory  capacity  [9].  Natural  T  regulatory
cells (Tregs) represent approximately 5-10% of CD4+ T cells
and express the intracellular transcription factor Foxp3 [10,11].
Accumulating evidence from both animal models and clinical
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induction and maintenance of allograft tolerance [12–14]. The
localization of Tregs in the graft after transplant is important for
effectively controlling aggressive immune reactivity to the graft
[15–18].  Investigators  have  found  that  stable  lung  transplant
recipients  have  an  increased  percentage  of  Tregs  in
bronchoalveolar lavage (BAL) fluid compared to subjects with
subsequent  lung  allograft  dysfunction,  suggesting  Tregs  may
control  the  alloimmune  response  in  the  lung  [19].  A  better
understanding of the mechanisms controlling Treg function and
expansion  may  lead  to  better  therapies  for  lung  transplant
recipients.
Costimulatory  molecules  are  known  to  regulate  the
development  and  function  of  Tregs  [20].  Mouse  and  human
Tregs express the negative regulator CTLA-4 and blockade of
CTLA-4  leads  to  a  decrease  in  alloantigen-specific  Treg-
mediated  suppression  [21–25].  CD28  is  also  known  to  be
important for Treg differentiation and homeostasis as targeted
mutations in CD28, as well as blockade of the CD28/B7-1/B7-2
pathway during development result in a remarkable decrease
in Treg numbers [26,27]. More recently, inducible costimulator
(ICOS) has been found to be required for optimal Treg function
and  development  [28–31].  ICOS  has  been  found  to  be
expressed  by  Tregs  infiltrating  the  lung  during  viral  infection
and  is  suggested  to  play  a  role  in  controlling  CD8-mediated
inflammation in the skin [30,31]. However, the requirement for
ICOS-expression by Tregs in the lung to control CD8-mediated
lung injury is not known.
In this study, we have used a previously developed model of
antigen-specific  T  cell  mediated  acute  bronchiolitis  using
transgenic  animals  expressing  transmembrane  ovalbumin
(OVA)  in  the  small  airway  epithelium  of  the  lung  under  the
control of the Clara cell promoter (CC10) [32]. Adoptive transfer
of in vitro activated OVA-specific CD8+ T cells from OVA TCR
transgenic  (OT-I)  mice  induces  lung  pathology  similar  to
findings  in  humans  with  acute  lung  transplant  rejection  and
virus-  induced  lung  injury.  By  adjusting  the  conditions  for
activated  OT-I  transfer,  we  have  used  this  model  in  CC10-
OVA.RAG-/- mice to dissect the mechanism by which bystander
cells modulate lung rejection. We found that neutrophils were
not  required  for  lethal  lung  injury  and  ICOS+  Tregs  were
significantly  increased  in  the  lung  during  acute  inflammation.
Moreover,  ICOS-/-  lymphocytes  were  not  sufficient  to  prevent
death  in  CC10-OVA.RAG-/-  mice  but  wild-type  Tregs  could
rescue this defect. These data suggested that ICOS expression
regulated  the  ability  of  CD4+  Tregs  to  suppress  CD8  T  cell
mediated lung injury.
However,  when  equal  numbers  of  ICOS-/-  Tregs  were
transferred  compared  to  wild-type  Tregs,  ICOS-/-  Tregs  were
able to prevent lethal lung injury. Our data suggest ICOS may
be  required  for  Treg  development  but  is  not  necessarily
required for Treg effector function in the lung.
Materials and Methods
Ethics Statement
All animal studies were done in concordance with principles
set forth by the Animal Welfare Act and the National Institutes
of  Health  guidelines  for  the  care  and  use  of  animals  in
biomedical  research.  All  experimental  mouse  protocols  were
approved by the Institutional Animal Care and Use Committees
of the University of Chicago and Indiana University School of
Medicine.
Animals
C57BL/6  mice  (4-  to  6-wk-old)  were  purchased  from  the
National Cancer Institute (Frederick, MD), Harlan Laboratories
(Indianapolis,  IN)  or  bred  in  house.  B6.CC10-OVA  (Thy1.2,
C57BL/6) mice were generated as previously described [32].
OT-I. Thy1.1 T cell receptor transgenic mice were a gift of Dr.
Yang-Xin  Fu  (University  of  Chicago).  CC10-OVA  mice  were
crossed  to  B6.RAG-1-/-  mice  purchased  from  Jackson  Labs
(Bar Harbor, ME to generate B6.CC10-OVA.RAG-/-mice. ICOS-/-
mice),  were  backcrossed  to  C57Bl/6  for  greater  than  10
generations  or  purchased  from  Jackson  Labs  (Bar  Harbor,
ME).  All  mice  were  housed  under  specific  pathogen-free
conditions in the animal care facility at University of Chicago or
Indiana University School of Medicine.
Activated OT-I T cell preparation
Preparation of OT-I CD8+ CTL was modified from previously
published  methods  [32,33].  Cellular  suspensions  were
prepared  from  the  spleen  and  lymph  nodes  of  OT-I.  Thy1.1
mice and cultured for 3 days with 1µg/ml OVA peptide antigen
(SIINFEKL), 1 µg/ml anti-CD28 (BioXcell), 25U/ml murine IL-2
(NIH), and 10 ng/ml recombinant mouse IL-12 (Invitrogen) in
10% FCS DMEM medium in 24-well plates. Cells were then
transferred to 75 ml flask and cultured with either 12.5U/ml IL-2
(low  IL-2)  or  25U/ml  (high  IL-2).  OT-I  CTL  for  transfer  were
harvested 24 hours later.
Adoptive transfer and depletion experiments
Activated  OT-I.  Thy1.1  CTL  were  prepared  as  mentioned
above. Live cells were separated by centrifugation through a
ficoll  gradient.  Cells  were  washed  and  resuspended  in  PBS,
and the indicated numbers of cells were injected i.v. via the
retro-orbital  venous  plexus.  Unfractionated  lymphocytes
transfer: spleen and lymph nodes were harvested from C57Bl/6
or ICOS-/- mice to generate single cell suspensions. Cells were
washed,  red  cells  lysed  with  ACK  lysis  buffer  (spleen),
centrifuged  through  ficoll  gradient  to  harvest  live  cells  and
washed  and  resuspended  in  PBS.  50x106  single  cells  were
transferred  via  retro-orbital  sinus  2  days  prior  to  the
intravenous administration of activated OT-I T cells. CD4+ T cell
depleted lymphocytes: C57Bl/6 spleen and lymph nodes were
harvested  and  processed  into  single-cell  suspensions.  Cells
were incubated with anti-CD4 antibody (RL172.4) at 4oC for 1
hour  followed  by  incubation  with  rabbit  complement  for  30
minutes  at  37oC  and  recovery  of  non-CD4+  T  cells  by  ficoll.
Depletion was confirmed by flow cytometry and over 90% of
CD4+  T  cells  were  depleted.  The  CD4-depleted  cells  were
resuspended in PBS and 50x106 single cells were transferred
i.v.  2  days  prior  to  the  intravenous  injection  of  OT-I  T  cells.
Alternatively, CD4+ T cells were depleted using CD4 depletion
kit  according  to  manufacturer’s  instructions  (Miltenyi  Biotec).
Tregs  were  isolated  from  spleen  and  lymph  node  using  the
ICOS+ T Cells Promote Resolution of Lung Injury
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manufacturer’s  instructions  (Miltenyi  Biotec).  Tregs  were
transferred i.v. along with ICOS-/- splenocytes or CD4-depleted
splenocytes  two  days  prior  to  the  transfer  of  OT-I  T  cells.
Neutrophil depletion: mice were injected i.p. 2 days before OT-I
transfer and 3 and 5 days after transfer with 300 µg anti-Ly6G
antibodies (1A8, BioXcell) or 300 µg isotype control antibody
(2A3,  BioXcell).  Mice  were  followed  daily  for  morbidity  and
were counted as a mortality if >20% weight loss was found.
Lung histology, digestions and bronchoalveolar lavage
(BAL)
Lungs were fixed in 10% formalin and embedded in paraffin
for  H&E  staining.  Lung  cell  preparation  has  been  previously
described  [34].  Lung  fragments  were  digested  with  150u/ml
collagenase I for 30 min at 37° C and then gently pipetted for 1
min. Single-cell suspensions were stained for flow cytometry.
For  BAL,  lungs  were  lavaged  with  four  consecutive  washes
with  0.8  ml  PBS,  and  3  ml  of  pooled  lavage  fluid  was
recovered. White cells were counted and stained with targeted
antibodies for flow cytometry.
Flow cytometry
Cell  surface  staining:  cells  from  lung  and  BAL  were
incubated with Fc block (2.4G2 antibody) and then stained with
APC-anti-CD3, APC-Cy7-anti-CD8, PE-anti-Gr1 (Ebioscience),
and  PE-Cy7-anti-Thy1.1  (Biolegend)  in  FACS  buffer  (PBS
containing 2% BSA and 0.01% sodium azide) on ice for 30 min.
Neutrophils were identified by characteristic size by FSC and
Gr1Hi  staining.  Intracellular  staining  for  Foxp3:  staining  was
conducted using the anti-Mouse/Rat Foxp3 Staining Set APC
according  to  the  manufacturer’s  instructions,  with  some
modifications  (eBioscience).  Lung  cells  were  washed  after
incubation  with  FITC-anti-ICOS  (from  Biolegend),  PerCp-
Cy5.5-anti-CD4,  PE-anti-CD25,  and  resuspended  in  FoxP3
fixation/permeabilization  buffer  (eBioscience),  and  then
incubated  for  10  min  at  4°  C,  washed  twice  in  FoxP3
permeabilization  buffer  (eBioscience),  and  stained  with  anti-
Foxp3-APC in Foxp3 permeabilization buffer for 1 h at 4° C.
Cells were then washed twice in Foxp3 permeabilization buffer
and  resuspended  in  FACS  buffer.  Intracellular  cytokine
staining:  cells  were  incubated  with  PMA  (20ng/ml)  and
ionomycin (2 µg/ml) for 5 Hours and Brefeldin A (10µg/ml) was
added for the last 4 hours of culture. Cells were stained with
surface stains for CD8, Thy1.1 and CD3, fixed with 2% PFA
and then permeabilized with 0.1% saponin buffer and stained
intracellularly  with  anti-Interferon-  γ,  anti-TNF-α  or  the
respective isotype controls. Cells were acquired with an LSR-II
flow  cytometer  (BD  Biosciences)  and  analyzed  with  FlowJo
software (Tree Star, Ashland, OR).
Treg in vitro cytokine expression: ELISA and qRT-PCR
Spleen and lymph node were harvested from C57BL/6 ICOS +/+
and  ICOS -/-   mice,  and  Treg  were  separated  using  mouse
CD4+CD25+ Regulatory T Cell Isolation Kit (Miltenyi Biotec). 4 x
105 cells were stimulated with 0.5µg/mL anti-CD3 and 100 U
IL-2  and  cultured  at  37°  C  for  72  hours  [35].  Culture
supernatants were harvested and analyzed with Mouse IL-10
ELISA MAX Standard Sets (BioLegend). For qRT-PCR, RNA
was isolated from ex vivo and activated CD4+CD25+ Treg using
RNeasy  Mini  Kit  (Qiagen)  and  stored  at  -80°  C.  cDNA  was
generated  with  qScript  cDNA  SuperMix,  and  qRT-PCR  was
immediately  performed  using  PerfeCTaTM  SYBR  Green
FastMixTM, Low ROXTM (Quanta Biosciences) and the following
primers:  (Il10)  5’-  GGTTGCCAAGCCTTATCGGA-3’,  5’-
ACCTGCTCCACTGCCTTGCT-3’;  (Tgfβ1)  5’-
TGACGTCACTGGAGTTGTACGG-3’,  5’-
GGTTCATGTCATGGATGGTGC-3’;  (Ebi3)  5’-
AGCAGCAGCCTCCTAGCCT-3’,  5’-
ACGCCTTCCGGAGGGTC-3’;  (Il12a)  5’-
TGGCTACTAGAGAGACTTCTTCCACAA-3’,  5’-
GCACAGGGTCATCATCAAAGAC-3’;  and  (β-actin)  5’-
GGCTGTATTCCCCTCCATCG-3’,  5’-
CCAGTTGGTAACAATGCCATGT-3’.  Relative  quantification
(RQ) values were calculated relative to β-actin and presented
as fold change compared to ICOS+/+ unstimulated samples.
Treg in vitro proliferation and survival analysis
Spleen and lymph node were harvested from C57BL/6 ICOS
+/+
and  ICOS
-/-
prepared.  Cells  were  resuspended  and  labeled  with  2  µM
CFSE (Sigma) for 10 minutes at room temperature. Labeled
cells were left unstimulated or stimulated with 0.01 µg/ml or 0.1
µg/ml anti-CD3ε antibody (2C-11) for 72 hours in DMEM + 5%
FCS  at  37°  C.  Cells  were  harvested  and  incubated  with  Fc
block (2.4G2 antibody). Dead cells were labeled using near-IR
LIVE/DEAD Fixable Dead Cell Stain Kit (Invitrogen). Cells were
stained  with  PerCP-Cy5.5-anti-CD4  (BioLegend);  stained  for
intracellular Foxp3 and analyzed by flow cytometry as outlined
above.
Statistical analysis
All data are expressed as mean and SEM unless otherwise
noted  in  the  legend.  Statistical  significance  was  determined
using  GraphPad  Prism  5.0  as  indicated  in  the  legends.
Differences were considered significant at p < 0.05.
Results
CD8+ induced lethal lung injury is dependent on IL-2
levels during CD8 T cell differentiation
As previously shown, CC10-OVA mice adoptively transferred
with 5x105 activated OT-I CTL die within 6 days due to severe
lung  injury,  while  transfer  of  a  lower  amount  of  OT-I  cells
(1x105)  decreases  mortality  (Figure  1)  [32,36].  As  the  mice
receiving 1x105 OT-I cells still had significant mortality with only
40%  surviving,  we  wanted  to  develop  a  model  where  lung
injury  was  induced  but  the  majority  of  mice  survived.  This
would  allow  us  to  dissect  the  mechanisms  promoting  and
controlling CTL-mediated injury in the lung. CD8 T cell effector
function  and  cytotoxicity  have  previously  been  shown  to  be
highly  dependent  on  the  amount  of  IL-2  available  during
differentiation [37–40]. We found that decreasing the amount of
IL-2  in  the  OT-I  cultures  from  25U/ml  (high  IL-2)  by  half  to
12.5U/ml (low IL-2) at the time of culture expansion on Day 3,
ICOS+ T Cells Promote Resolution of Lung Injury
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  mice,  and  single-cell  suspensions  weresignificantly  altered  the  lethality  of  the  transferred  OT-I.
Transfer of 5x105 OT-I cells cultured with low IL-2 resulted in
significantly decreased mortality compared to the 5x105 OT-I
cultured under high IL-2 conditions and transfer of 1x105 OT-I
cultured with low dose IL-2 did not induce death in any of the
mice. The lethality of CTL in this model was not only dependent
on the number of cells transferred but the level of IL-2 given to
the CTL at the time of culture expansion.
Acute lung inflammation mediated by activated
antigen-specific CD8+ T cells recruits bystander T cells
While the CC10-OVA mice injected with 1x105 low dose IL-2
OT-I cells survived, an acute inflammatory response was still
evident in the lungs. There was an increase in the frequency of
T cells, neutrophils, and transferred OT-I T cells in the BAL and
lungs of CC10-OVA mice compared to B6 controls (Figure 1B,
1C). The immune response in the lungs of the CC10-OVA mice
was also marked by an increase in endogenous (Thy1.2) CD8+
and  CD4+  T  cells  (Figure  1B).  The  lungs  of  the  CC10-OVA
mice  compared  to  controls  had  moderate  perivascular  and
peribronchial inflammatory cell infiltration on day 4 (Figure 1D).
By Day 30 the inflammation had completely resolved (data not
shown).  These  data  suggested  neutrophils  and  lymphocytes
recruited to the lung were playing a role in the injury induced by
CD8+ T cells. CD4+
T cells are required for the resolution of acute lung
inflammation
To test the hypothesis that lymphocytes recruited to the lung
were contributing to the inflammatory response in the CC10-
OVA  mice,  we  bred  the  CC10-OVA  mice  to  B6.RAG-/-  to
generate  B6.CC10-OVA.RAG-/-  (Thy1.2)  and  B6.RAG-/-
(littermate control, Thy1.2) mice. The requirement for bystander
lymphocytes  to  induce  CD8-mediated  lung  injury  was
investigated  by  transferring  1x105  activated  OT-I.  Thy1.1  T
cells  (low  IL-2)  into  CC10-OVA.RAG-/-  mice  or  controls  as
outlined  in  Figure  2.  All  of  the  CC10-OVA.RAG-/-  (No  Sp  >
CC10.OVA.RAG-/-) mice died after OT-I transfer but none of the
control mice (No Sp > B6.RAG-/-) (Figure 2B). We expected that
the  inflammation  may  be  less  in  the  absence  of  other
lymphocytes but instead the bystander lymphocytes recruited
to  the  lung  were  protective.  One  explanation  for  this  finding
was that uncontrolled homeostatic proliferation contributed to
death. Previous work by Surh and colleagues suggested that
50x106 whole splenocytes diminish homeostatic proliferation in
RAG-/-  mice  [41].  To  prevent  homeostatic  proliferation  and
determine  the  role  of  bystander  lymphocytes,  50x106
splenocytes from B6 (Thy1.2) mice were transferred two days
prior to transfer of activated OT-I. Thy1.1 T cells, see timeline
(Figure  2A).  All  CC10-OVA.Rag-/-  mice  given  bulk  B6  lymph
node/spleen  cells  (Sp  >  CC10.OVA.RAG-/-)  survived  for  30
days (Figure 2B). Perivascular and peribronchial inflammatory
cell infiltrates were found in the lungs similar to that seen in
CC10-OVA  mice  (Figure  2C).  The  BAL  also  had  increased
numbers of total cells, CD3+ T cells and neutrophils compared
to controls (Figure 2D). The cell counts were highest at Day 4
and decreased to the level of controls by Day 10. These data
were  consistent  with  the  day  10  lung  pathology  where  few
infiltrates  remain.  Complete  resolution  was  found  by  Day  30
(Figure 2C). Lungs or airways from control B6.Rag-/- mice on
day 4 and day 30 did not have any significant cellular infiltration
(Figure 2C, 2D).
Given  the  increase  in  CD4+  T  cells  in  the  B6.CC10-OVA
mice, we investigated whether CD4+ T cells were playing a role
in the inflammatory response. CC10-OVA.RAG-/- mice received
either  bulk  lymphocytes  (combined  lymph  node/spleen)  or
CD4-depleted  lymphocytes  two  days  prior  to  i.v.  injection  of
OT-I.  Thy1.1  T  cells.  All  CC10-OVA.RAG-/-  mice  given  CD4-
depleted splenocytes died within 8 days, while the majority of
the mice given bulk splenocytes survived (Figure 3A). These
data  suggest  that  bystander  CD4+  T  cells  are  necessary  for
resolution of acute lung inflammation in our model.
Neutrophils are not required for CD8+ T cells to induce
lethal lung injury
To determine the mechanism by which the CD4+ T cells may
be  regulating  the  inflammation  in  the  lung  we  evaluated  the
BAL on Day 4 at the peak of inflammation and before mortality
increased.  In  the  absence  of  CD4+  T  cells  there  was  a
significant  increase  in  the  percentage  of  OT-I  T  cells  and  a
trend toward increased neutrophils (Figure 3B). As expected in
the absence of CD4+ T cells there were more Thy1.2 + CD8+ T
cells  than  Thy1.2  +  CD8-  T  cells  (Figure  3B).  While  the
percentage of neutrophils was not significantly increased it was
still possible that neutrophils were contributing to the lethal lung
injury by persisting in the CC10-OVA.RAG-/- mice given OT-I T
cells  alone  or  CD4-depleted  lymphocytes.  CD4+  Treg  have
previously  been  found  to  regulate  neutrophil  apoptosis  in  a
mouse model of LPS induced acute lung injury [42]. To test this
possibility  we  depleted  neutrophils  using  anti-Ly6G  (1A8)
antibody,  known  to  specifically  deplete  neutrophils  and  not
monocytes  [43–45].  In  Figure  4A,  we  found  that  injection  of
anti-Ly6G  was  sufficient  to  deplete  neutrophils,  defined  as
Gr1Hi  and  also  CD11b+Ly6G+  (data  not  shown),  in  the  lungs
and  spleen  compared  to  the  isotype  control  antibody  (2A3).
However,  neutrophil  depletion  in  the  CC10-OVA.RAG-/-  mice
given OT-I T cells did not protect the mice from death (Figure
4B).  Neutrophils  were  not  required  for  CD8-mediated  lethal
lung injury in our model.
CD4+CD25+Foxp3+ T cells in the lungs are ICOSHi
In B6.CC10-OVA mice we had found a significant increase in
CD4+ T cells in the lungs and BAL after transfer of activated
OT-I T cells (Figure 1A, 1B). Previous work in this model has
found  a  role  for  CD4+Foxp3+  Tregs  in  regulating  the
inflammatory response in the lung [36]. We also confirmed that
the  percentage  and  number  of  CD4+Foxp3+  Treg  cells  was
significantly higher in B6.CC10-OVA mice compared to control
B6 mice (Figure 5A and data not shown). Since our previous
work has shown a role for ICOS in CD4+ Th2 effector function
and migration to the lungs and others have found that ICOS
expression  regulates  Treg  function,  we  compared  ICOS
expression  to  CD25  expression  on  Treg  in  the  lung
[29,30,46,47].  We  found  that  the  frequency  and  absolute
numbers of ICOS  HiCD25Hi Tregs were significantly higher in
the lungs of CC10-OVA mice than wild-type mice (Figure 5 B,
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PLOS ONE | www.plosone.org 4 August 2013 | Volume 8 | Issue 8 | e72955Figure 1.  Acute lung inflammation induced by antigen-specific CD8+ T cells cultured with low dose IL-2 resolves.  CC10-
OVA. Thy1.2 transgenic mice or controls (B6.Thy1.2) were injected i.v. with the indicated numbers of activated OT-I. Thy1.1 T cells
expanded with either high dose IL-2 (25U/ml) or low dose IL-2 (12.5U/ml). (A) Survival was dependent on the number of OT-I
transferred and the dose of IL-2 given during culture. (B) The percentage of neutrophils (gated by size and Gr1Hi), CD3+Thy1.2+ and
OT-I. Thy1.1+ T cells were measured in the BAL. (C) The numbers of cells in the lungs were measured on Day 4 after transfer of
OT-I T cells. (D) Lung histology 4 days after transfer demonstrates peribronchial and perivascular mononuclear infiltrates in CC10-
OVA mice compared to B6 mice; 7 µm sections were stained with H and E, magnification, 10X. Unpaired t tests were used to
determine significance between controls (B6) and CC10-OVA mice, *p<0.05, **p<0.01, ***p<0.0001.
doi: 10.1371/journal.pone.0072955.g001
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CC10-OVA mice (~80%) expressed high levels of ICOS (Figure
5C,  D).  In  contrast,  control  B6  mice  had  on  average  ~40%
ICOSHi  Treg  and  Treg  were  either  ICOSHi  or  CD25Hi  (Figure
5C,D). These data suggest that in response to inflammation in
the lung Treg are activated and as a consequence upregulate
ICOS along with CD25. Interestingly, when we evaluated ICOS
expression  on  CD4+Foxp3+  Treg  after  transfer  into  B6.RAG-/-
controls  or  CC10-OVA.RAG-/-  mice  given  activated  OT-I
(schema in Figure 2), no difference in ICOS expression was
found between the two groups. Thus, ICOS expression may be
induced  on  Tregs  in  response  to  homeostatic  proliferation
irrespective of inflammatory signals.
ICOS-/- lymphocytes do not protect from CD8-mediated
lung injury
Since  ICOS  was  highly  expressed  on  Tregs  during  the
inflammatory response in the lungs, we tested the ability of T
cells  from  ICOS-/-  mice  to  inhibit  lethal  lung  injury.  Bulk
Figure 2.  Bystander lymphocytes are required to resolve lung injury mediated by OT-I.  CC10-OVA.RAG-/- or B6.RAG-/- mice
were given 1x105 OT-I activated in vitro with low dose IL-2 on Day 0. On Day -2, some animals received 5x107 lymph node (LN) and
spleen cells from B6 wild-type mice. Mice were sacrificed and lungs and BAL were analyzed at different time-points as indicated. (A)
Experimental  plan  is  outlined.  (B)  CC10-OVA.RAG-/-  mice  that  received  only  OT-I  T  cells  died  within  7  days  (No  sp  >  CC10-
OVA.RAG-/-).  CC10-OVA.RAG-/-  mice  that  received  LN/spleen  cells  2  days  prior  to  transfer  of  OT-I  survived  (Sp  >  CC10-
OVA.RAG-/-). Control mice were not affected (No Sp > B6.RAG-/-). (C) Lung tissue was harvested from CC10-OVA.RAG-/- given LN/
spleen cells prior to OT-I transfer and B6.RAG-/- mice on days 4 and 30 after transfer of OT-I T cells. Sections (7 µm) were stained
with H and E. Original magnification: 10X. (D) BAL from CC10-OVA.RAG-/- mice given LN/spleen cells prior to OT-I transfer and
controls was harvested and analyzed on days 4, 6, and 10 after adoptive transfer of 1x105 OT-I T cells. Results are the mean ±
SEM, CC10-OVA. RAG-/- mice (n=3), B6.RAG-/- (n=3) at each time-point.
doi: 10.1371/journal.pone.0072955.g002
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transferred into CC10-OVA.RAG-/- mice prior to the transfer of
activated OT-I T cells as outlined in Figure 2. The majority of
mice that received ICOS-/- splenocytes died within 8 days and
all ICOS-/- recipients were dead by 30 days (Figure 6A). On day
4 after OT-I transfer, the lungs from mice given WT or ICOS-/-
cells prior to OT-I transfer had similar numbers of total cells
and there were no significant differences in the percentages of
neutrophils (Figure 6B and data not shown). In addition, there
were  no  differences  in  the  frequency  or  number  of  CD4+,
CD4+Foxp3+, or OT-I. Thy1.1+ T cells between the two groups.
There was a significant difference in the frequency of non-OT-
I.CD8 + Thy1.2+ T cells in the absence of ICOS but the absolute
numbers of these cells was not different. There were also no
differences in the frequency of IFNγ or TNFα producing OT-I T
cells  or  CD8+Thy1.2  cells.  To  determine  if  the  defect  in  the
mice  receiving  ICOS-/-  splenocytes  was  specifically  due  to  a
defect  in  Tregs,  we  transferred  5x105  or  1x106  CD4+CD25+
  Tregs  from  wild-type  mice  along  with  ICOS-/-  splenocytes.
Transfer of 1x106 wild-type Tregs but not 5x105 wild-type Tregs
was  sufficient  to  prevent  death  and  resolve  the  acute  lung
inflammation with the majority of mice alive at 30 days (Figure
6A). These data suggested that ICOS-/- Tregs were defective in
regulating CD8-mediated lung immunopathology.
ICOS-/- Tregs have defects in IL-10 production and
proliferation
To further investigate the effect of ICOS deficiency on Tregs,
we  compared  expression  of  the  regulatory  cytokines  IL-10,
IL-35, and TGF-β1 in unstimulated and stimulated ICOS+/+ Treg
to ICOS-/- Treg. Treg have been found to utilize IL-10 and TGF-
β1 to suppress dendritic cell and T cell function and high ICOS
expression  has  been  associated  with  IL-10  producing  Treg
[29,48]. IL-35, a novel heterodimeric cytokine comprised of the
IL-12α (p35) and EBV-induced gene product (EBI-3) subunits,
has also been associated with high ICOS expressing Treg in a
Figure 3.  CD4+ T cells are required to prevent lethal lung injury.  CC10-OVA. RAG-/- mice were injected with LN/spleen cells or
CD4  depleted  LN/spleen  Thy1.2  cells  2  days  prior  to  i.v.  injection  of  activated  1x105  OT-I.  Thy1.1  T  cells.  (A)  Survival  was
dependent  on  CD4+  T  cells.  (B)  Day  4  after  OT-I  transfer,  frequency  of  BAL  cells  was  measured  in  B6.RAG-/-  compared  to
CC10.OVA.RAG-/- with or without CD4 depletion of LN/spleen cells.
doi: 10.1371/journal.pone.0072955.g003
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stimulated  in  vitro,  ICOS-/-  CD4+CD25+  T  cells  expressed
significantly less Il10 than ICOS+/+ CD4+CD25+ T cells (Figure
7A).  However,  no  significant  differences  were  observed  in
expression  of  the  subunits  of  IL-35,  Ebi3  or  Il12a,  or  Tgfb1,
suggesting  ICOS-/-  Treg  have  no  defect  in  IL-35  or  TGF-β1
expression (Figure 7A). In addition, ICOS-/- CD4+CD25+ T cells
secreted significantly less IL-10 than ICOS+/+ Treg (Figure 7B).
No differences were observed in ex vivo cytokine expression
levels between ICOS+/+ and ICOS-/- CD4+CD25+ T cells (Figure
7A).
While ICOS has been previously linked to IL-10 expression,
ICOS expression has also been associated with differences in
Treg proliferation and survival. Chen, et al. identified two sub-
populations of murine Treg: an ICOSHi hyperproliferative subset
and  an  ICOSLo  death-prone  subset  [50].  These  results
suggested ICOS-/- Tregs may have defects in proliferation and
survival.  We compared  the  proliferative  capacity  and
susceptibility to death in vitro of CD4+Foxp3+ Tregs from ICOS
+/+ to ICOS-/- mice. We found a slight decrease in proliferative
capacity  with  ICOS-/-  Tregs  (Figure  7C).  This  defect  was
specific to ICOS-/- CD4+Foxp3+ Treg and was not observed in
ICOS-/-  CD4+Foxp3-  conventional  T  cells  (data  not  shown).
There  was  no  defect  in  survival  of  CD4+Foxp3+  Treg  from
ICOS-/-  mice  compared  to  wild-type  (Figure  7D).  Taken
together,  these  results  suggest  that  ICOS  expression  is
important  for  the  proliferation  potential,  but  not  survival,  of
Treg.
No defect of ICOS-/- CD4+CD25+ Treg in vivo when
directly compared with wild-type Treg
While  our  data  suggested  that  ICOS-/-  CD4+CD25+  Tregs
have a defect in vivo and in vitro, one possibility for our in vivo
findings was that ICOS-/- mice have less Tregs than wild-type
mice [28,51]. In our experiments with transferring bulk lymph
node  and  splenocytes,  we  estimated  that  5x105  Treg  were
being transferred. However, in Figure 6, we found that ICOS+/+
5x105 CD4+CD25+ Treg were not sufficient to protect the mice
receiving ICOS-/- lymphocytes while 1x106 Treg did protect. To
directly compare equal numbers of ICOS+/+ and ICOS-/- Treg in
vivo in our model in the absence of other CD4+ Treg, 1x106
CD4+CD25+ Treg from ICOS+/+ or ICOS-/- mice were transferred
along with CD4-depleted lymphocytes from wild-type mice into
CC10-OVA.RAG-/- mice 2 days prior to the transfer of activated
OT-I. These mice were compared to mice that received only
CD4-depleted splenocytes. As found in Figure 3, CD4-depleted
splenocytes were not protective from lethal lung injury (Figure
8).  Contrary  to  expectations,  we  did  not  find  a  difference  in
survival  between  mice  that  received  ICOS+/+  or  ICOS-/-  Treg.
There were no differences in the time to maximum weight loss
or the overall weight loss in the animals that survived in either
group  (data  not  shown).  These  data  suggest  that  ICOS-/-
CD4+CD25+  Treg  can  protect  from  lethal  lung  injury  when
sufficient numbers are transferred.
Discussion
In a model of lung rejection, we have found that mice given a
low  dose  of  activated  antigen-specific  CD8+  T  cells  have
reproducible  lung  inflammation  that  requires  bystander
lymphocytes  to  express  ICOS  for  resolution  of  lung
inflammation.  In  the  absence  of  exogenous  lymphocytes,
CC10-OVA.RAG-/- mice succumbed to lethal lung rejection from
activated OT-I T cells. CD4+ T cells were required for resolution
and  ICOS-/-  lymphocytes  were  not  sufficient  to  protect  the
CC10.OVA.RAG-/-  mice  from  the  lethal  lung  injury.  Wild-type
Tregs were sufficient to rescue this defect. Tregs from ICOS-/-
mice  had  defects  in  proliferation  and  IL-10  expression  and
Figure 4.  Neutrophils are not required for lethal lung injury.  CC10-OVA.RAG-/- mice were injected with anti-Ly6G antibody or
isotype control antibody i.p. two days prior to transfer of OT-I T cells and on days 3 and 5 after OT-I transfer. (A) Anti-Ly6G antibody
(dotted line) specifically depleted neutrophils (Gr1Hi) cells in both the lung and spleen as demonstrated by the absence of the Gr1Hi
peak by histogram compared to isotype control treated mice (solid line). Gray histogram is negative control for Gr1 staining. (B) No
difference in mortality between anti-Ly6G treated animals and isotype control treated animals was found.
doi: 10.1371/journal.pone.0072955.g004
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 Figure 5.  ICOS+ Tregs are increased in lungs of mice with CD8-mediated acute lung injury.  Lung cells were harvested and
analyzed by flow cytometry on day 4 after adoptive transfer of 1x105 OT-I T cells (low dose IL-2). (A) Frequency of CD4+ Foxp3+
Tregs  in  the  lungs.  (B)  Frequency  of  ICOS  +  CD25+  CD4+Tregs  in  the  lung;  data  are  representative  of  three  independent
experiments.  (C)  Representative  FACS  plot  from  lungs  of  control  or  CC10.OVA  mice.  (D)  Left  panel  is  ICOS  expression  on
CD4+Foxp3+ T cells from lungs of B6 (dotted line) and B6.CC10-OVA (solid line). Right panel is ICOS expression on CD4+Foxp3+
Tregs from lungs of B6.RAG-/- (dotted line) and B6.CC10-OVA.RAG-/- mice (solid line).
doi: 10.1371/journal.pone.0072955.g005
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directly compared to the same number of ICOS+/+ Tregs found
no differences in the ability to protect from lethal lung injury.
Our data suggest ICOS regulates the development of Tregs,
but ICOS is not required for Treg effector function in our model.
Our work extends previous work in this model demonstrating
that  the  balance  between  effector  T  cells  (Teff)  and  Treg
regulate  protection  from  lethal  lung  injury  in  B6.CC10-OVA
mice  [36].  In  addition,  to  differences  in  the  numbers  of  Teff
promoting  lethal  lung  inflammation  we  found  that  modulating
IL-2  levels  during  CTL  differentiation  affected  the  lethality  of
CTL  in  inducing  lung  injury.  These  data  are  consistent  with
studies  demonstrating  the  role  of  IL-2  in  augmenting  CD8
effector  function  and  cytotoxicity  through  increasing  the
transcription  factor,  eomesodermin  (Eomes),  and  repressing
BCL6 [39]. Thus the quantity of CTL and the quality of their
effector  functions  determine  the  outcome  of  injury.  As
previously reported, the quantity of Tregs transferred affected
their ability to prevent lethal lung inflammation [36]. Therapies
that  expand  Tregs  while  downregulating  the  activation  and
trafficking of Teff may prevent acute rejection.
Our findings support the role of ICOS in Treg development,
but  do  not  confirm  a  role  for  ICOS  in  natural  Treg  effector
function. This is despite the fact that Tregs from B6.CC10-OVA
mice  with  lung  rejection  expressed  high  levels  of  ICOS  and
ICOS+/+ Treg, when present in sufficient numbers, were able to
prevent death in mice that received ICOS-deficient bystander
lymphocytes.  These  data  suggested  that  ICOS  would  be
Figure 6.  ICOS-/- lymphocytes do not protect from CD8-mediated lung injury in mice.  CC10-OVA.RAG-/- mice were injected
with wild-type LN/spleen cells, ICOS deficient LN/spleen cells, or ICOS deficient LN/spleen cells co-transferred with 0.5x106 or
1x106 ICOS+/+ Tregs 2 days prior to i.v. injection of activated 1x105 OT-I T cells. (A) Survival (B) Total lung cells, percentage and
absolute numbers of CD4+, CD4+Foxp3+ T cells. (C) Percentage and absolute number of OT-I. Thy1.1+ cells and CD8+ Thy1.2+ T
cells. (D) Percentage and absolute number of OT.I. Thy1.1+ T cells and CD8+Thy1.2+ T cells expressing IFNγ or TNFα in the lungs
at Day 4 were measured.
doi: 10.1371/journal.pone.0072955.g006
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consistent with previous studies using ICOS-/- mice [48,51]. In
contrast  to  expectations,  we  found  that  mice  that  received
equal numbers of ICOS-/- Tregs compared to wild-type Tregs
did not succumb to lethal lung injury. Our data suggest that the
deficiency  found  with  bystander  ICOS-/-  lymphocytes  may  be
related to a defect in Treg development and the numbers of
Treg, rather than a defect in their effector function in vivo in this
model.  This  would  be  consistent  with  findings  in  a  previous
study that ICOS-/- mice could develop functional CD4+ Treg in a
model of tolerance [52].
Alternatively,  bystander  ICOS-/-  lymphocytes  may  be
contributing to the lung injury. There was a significant increase
in the frequency of CD8+Thy1.2+ T cells in mice that received
ICOS-/- lymphocytes compared to mice that received wild-type
lymphocytes,  but  there  was  no  difference  in  the  absolute
number of these cells. Further, no differences were detected in
the frequency of ICOS-/-CD8+Thy1.2+ T cells producing TNFα,
the major cytokine produced by these cells, or IFNγ, which only
a few of these cells produced. There were very low numbers of
dual  producers.  In  addition,  at  the  peak  of  inflammation,  no
differences were found in the expansion of the OT-I T cells in
mice that received ICOS-/- lymphocytes compared to mice that
received  wild-type  lymphocytes.  Thus,  we  did  not  find
conclusive evidence of augmented responses in vivo from the
bystander  ICOS-deficient  T  cells  or  the  transferred  CTL  to
suggest  ICOS-/-  lymphocytes  were  contributing  to  the  lung
injury.  Another  possibility  is  that  Tregs  function  via  other
lymphocytes  which  are  defective  in  ICOS-/-  mice,  which  has
been suggested by others [52]. However, we found that ICOS+/+
Tregs were effective in controlling inflammation in the presence
of ICOS-/- lymphocytes which would make this possibility less
likely. More studies are needed to determine the contribution of
ICOS-/- lymphocytes to the lung injury in our model.
Figure 7.  ICOS-/- Tregs have defects in IL-10 production and proliferation.  CD4+CD25+ Treg were isolated from C57Bl/6 ICOS
+/+ and ICOS-/- mice and stimulated for 72 hours in vitro with anti-CD3 and IL-2 (A and B). A) Regulatory cytokine expression was
measured by qRT-PCR. (B) IL-10 in the culture supernatants was measured by ELISA. C and D: single-cell suspensions of spleen
and lymph node cells from C57Bl/6 ICOS+/+ and ICOS-/- mice were CFSE labeled, cultured for 72 hours in the presence of anti-CD3,
and analyzed by flow cytometry. C. Percentage of CD4+Foxp3+ T cells that were CFSELo was measured. D. Survival of CD4+Foxp3+
T cells from ICOS+/+ and ICOS-/- mice was determined using a fixable live/dead dye (*p < 0.05, **p<0.01 – unpaired Student’s t test).
doi: 10.1371/journal.pone.0072955.g007
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been  of  interest  in  the  literature  and  several  groups  have
shown  in  both  humans  and  mice  differences  in  cytokine
production  and  proliferation  between  these  two  subsets  of
Tregs  [29,30,48,53].  Human  ICOS+  Tregs  produced  higher
levels of IL-10 and TGFβ than Tregs with low ICOS expression
ex vivo and similar results were found in a mouse model of
contact  hypersensitivity  [29,30].  Recent  work  has  also
associated IL-35 production with high ICOS expression on wild-
type Treg [49]. In addition, ICOS expression was associated
with a higher proliferative and survival capacity of Treg in vitro
[50].  We  investigated  whether  ICOS  deficiency  would  affect
cytokine expression, proliferation and survival of Treg in vitro.
Consistent  with  previous  studies  we  found  that  ICOS-/-  Treg
had  decreased  IL-10  mRNA  and  protein  after  in  vitro
stimulation compared to ICOS+/+ Treg [51,53,54]. However, we
did not find evidence of a likely defect in IL-35. In addition, we
found a minimal defect in proliferation in vitro for ICOS-/- Treg
compared to ICOS+/+ Treg and no defects in survival. These
data  suggest  that  high  ICOS  expression  may  distinguish  a
subset of Tregs in wild-type mice, but ICOS is not necessary
Figure  8.    ICOS-/-  Tregs  protect  from  lethal  lung
injury.    CC10-OVA.RAG-/-  mice  were  injected  with  CD4-
depleted  wild-type  LN/spleen  cells  in  combination  with  1x106
ICOS+/+CD4+CD25+ or ICOS-/-CD4+CD25+ Tregs 2 days prior to
i.v.  injection  of  activated  1x105  OT-I  T  cells.  Survival  was
compared.
doi: 10.1371/journal.pone.0072955.g008
for  all  of  the  characteristics  of  these  Tregs.  Instead,  ICOS
expression  may  be  a  marker  of  full  activation  of  Tregs  or
previous activation. This is consistent with the known induction
of ICOS upon T cell activation. Interestingly, under homeostatic
conditions in B6.RAG-/- mice, all Treg were ICOSHi despite a
portion  being  ICOSLo  prior  to  transfer.  Although  we  cannot
exclude  that  ICOSHi  Treg  preferentially  expand  under  these
conditions, we think it is possible that ICOS can be upregulated
on  all  Treg  upon  activation  and  proliferation.  Inflammatory
conditions and homeostatic proliferation appear to provide the
signals necessary for Treg to upregulate ICOS expression or
for ICOS+ Treg to expand.
In conclusion, we have found that tissue injury in the lung
induces recruitment of bystander lymphocytes and an influx of
activated Tregs, which express high levels of ICOS. With the
right  balance  of  Tregs  to  CTL  lung  homeostasis  can  be
restored  without  the  induction  of  fibrosis  or  any  evidence  of
chronic inflammation. Strategies that tip the balance in favor of
Tregs  may  be  more  protective  of  lung  allografts  than  global
immunosuppression. Furthermore, ICOS regulates the ability of
bystander  lymphocytes  to  resolve  CTL  mediated  lung  injury
and may be an important target for modulating lung rejection.
The mechanism by which ICOS affects bystander lymphocyte
function requires more investigation and may be due to defects
in  the  numbers  of  Tregs  in  ICOS-/-  mice.  While  ICOS  is  an
important  regulator  of  Treg  development,  ICOS  is  not
necessarily required for Treg effector function in the lung.
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